Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer

Expert Opinion on Biological Therapy

Volumn 14, Issue 3, 2014, Pages 365-376

  Adam, Valerie ^a   Wauters, Isabelle ^a   Vansteenkiste, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Adjuvant; Cancer vaccines; Immunotherapy; Lung cancer; Melanoma associated antigen A3

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; MAGEA3 PROTEIN, HUMAN; SUBUNIT VACCINE; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES; TREATMENT OUTCOME; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOPLASM PROTEINS; TREATMENT OUTCOME; VACCINATION; VACCINES, SUBUNIT;

EID: 84894201184     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.880421     Document Type: Article

References (48)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403
2. Vansteenkiste J, De Ruysscher D, Eberhardt W,et al. Early and locally advanced non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi89-98
3. Peters S, Adjei AA, Gridelli C,et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii56-64
4. Scagliotti G, Parikh P, Von Pawel J,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer. J Clin Oncol 2008;26:3543-51
5. Mok TS, Wu YL, Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
6. Goldstraw P, Crowley J, Chansky K,et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14
7. Arriagada R, Bergman B,et al. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-60
8. Younis T, Al-Fayea T, Virik K,et al. Adjuvant chemotherapy uptake in non-small cell lung cancer. J Thorac Oncol 2008;3:1272-8
9. Kantoff PW, Higano CS, Shore ND,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
10. Butts CA, Socinski MA, Mitchell P,et al. START: a phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 2013;31(Suppl): abstract 7500
11. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60
12. Roithmaier S, Haydon AM, Loi S,et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 2007;26:845-9
13. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52
14. Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-15
15. De Pas T, Giovannini M, Rescigno M,et al. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. Crit Rev Oncol Hematol 2012;83:432-43
16. Al-Shibli KI, Donnem T, Al-Saad S,et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-7
17. Zhuang X, Xia X, Wang C,et al. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010;18:24-8
18. Kawai O, Ishii G, Kubota K,et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV non-small cell lung cancer. Cancer 2008;113:1387-95
19. Trojan A, Urosevic M, Dummer R,et al. Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer. Lung Cancer 2004;44:143-7
20. Shimizu K, Nakata M, Hirami Y,et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5:585-90
21. Declerck S, Vansteenkiste J. Immunotherapy for lung cancer: ongoing clinical trials. Future Oncol 2014;10(1):91-105.
22. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009;9:57-63
23. Palucka K, Ueno H, Fay J,et al. Dendritic cells and immunity against cancer. J Intern Med 2011;269:64-73
24. Decoster L, Wauters I, Vansteenkiste J. Vaccination therapy for non-small cell lung cancer: review of agents in phase III development. Ann Oncol 2012;23:1387-93
25. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1
26. Van den Eynde BJ, Van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93
27. Gure AO, Chua R, Williamson B,et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:8055-62
28. Shigematsu Y, Hanagiri T, Shiota H,et al. Clinical significance of cancer/testis antigens expression in patients with nonsmall cell lung cancer. Lung Cancer 2010;68(1):105-10
29. Kim JH, Nakayama H, De PasT,et al. Patient and tumor characteristics impacting on MAGE-A3 expression: screening data from the MAGRIT Phase III trial. J Thorac Oncol 2011;6 Suppl, 662S.
30. Liu W, Cheng S, Asa SL,et al. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008;68:8104-12
31. Sienel W, Varwerk C, Linder A,et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 2004;25:131-4
32. Schnurr M, Chen Q, Shin A,et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005;105:2465-72
33. Atanackovic D, Altorki NK, Stockert E,et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004;172:3289-96.
34. Atanackovic D, Altorki NK, Cao Y,et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 2008;105:1650-5
35. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2010;667:111-23
36. Kruit WH, Suciu S, Dreno B,et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer melanoma group in metastatic melanoma. J Clin Oncol 2013;31:2413-20.
37. Marchand M, Punt CJ, Aamdal S,et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003;39:70-7
38. Vansteenkiste J, Zielinski M, Linder A,et al. Adjuvant MAGE-A3 immunotherapy in resected non-small cell lung cancer: phase II randomized study results. J Clin Oncol 2013;31:2396-403.
39. Pujol JL, Vansteenkiste JF, De Pas TM,et al. MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy. J Clin Oncol 2012;30(Suppl):abstract 7013
40. Ulloa-Montoya F, Louahed J, Dizier B,et al. Predictive gene signature in MAGEA3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31:2388-95.
41. Hoos A, Parmiani G, Hege K,et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30:1-15
42. Spigel DR, Ervin TJ, Ramlau RA,et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small cell lung cancer. J Clin Oncol 2013;31(32):4105-14
43. Yin B, Liu G, Wang XS,et al. Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder. Urol Oncol 2012;30:886-92
44. Cuffel C, Rivals JP, Zaugg Y,et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 2011;128:2625-34
45. Otte M, Zafrakas M, Riethdorf L,et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res 2001;61:6682-7
46. Shantha Kumara HM, Grieco MJ, Caballero OL,et al. MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immun 2012;12:16
47. Inoue H, Mori M, Li J,et al. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 1995;63:523-6
48. Linder A, Budihardjo-Welim H, Velehorschi W,et al. Prognostic value of MAGE-A3 and PRAME gene expression in non-small-cell lung cancer (NSCLC). J Clin Oncol 2012;30(Suppl):abstract 7056